484 related articles for article (PubMed ID: 27889312)
1. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.
Baulac M; Rosenow F; Toledo M; Terada K; Li T; De Backer M; Werhahn KJ; Brock M
Lancet Neurol; 2017 Jan; 16(1):43-54. PubMed ID: 27889312
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.
Baulac M; Brodie MJ; Patten A; Segieth J; Giorgi L
Lancet Neurol; 2012 Jul; 11(7):579-88. PubMed ID: 22683226
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.
Trinka E; Ben-Menachem E; Kowacs PA; Elger C; Keller B; Löffler K; Rocha JF; Soares-da-Silva P
Epilepsia; 2018 Feb; 59(2):479-491. PubMed ID: 29369348
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial.
Schmitz B; Dimova S; Zhang Y; Chellun D; De Backer M; Gasalla T
Epilepsy Res; 2020 Jan; 159():106220. PubMed ID: 31812127
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy.
Ben-Menachem E; Grebe HP; Terada K; Jensen L; Li T; De Backer M; Steiniger-Brach B; Gasalla T; Brock M; Biton V
Epilepsia; 2019 Dec; 60(12):2437-2447. PubMed ID: 31755090
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial.
Kwan P; Brodie MJ; Kälviäinen R; Yurkewicz L; Weaver J; Knapp LE
Lancet Neurol; 2011 Oct; 10(10):881-90. PubMed ID: 21889410
[TBL] [Abstract][Full Text] [Related]
7. Lacosamide in patients with epilepsy of cerebrovascular etiology.
Rosenow F; Brandt C; Bozorg A; Dimova S; Steiniger-Brach B; Zhang Y; Ferrò B; Holmes GL; Kälviäinen R
Acta Neurol Scand; 2020 Jun; 141(6):473-482. PubMed ID: 32068241
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed temporal lobe epilepsy: Post hoc analysis of a randomized, double-blind trial.
Terada K; Kubota Y; Dimova S; Elmoufti S; Floricel F; Chellun D; O'Brien TJ
Seizure; 2023 Nov; 112():62-67. PubMed ID: 37769545
[TBL] [Abstract][Full Text] [Related]
9. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study.
Wechsler RT; Li G; French J; O'Brien TJ; D'Cruz O; Williams P; Goodson R; Brock M;
Epilepsia; 2014 Jul; 55(7):1088-98. PubMed ID: 24915838
[TBL] [Abstract][Full Text] [Related]
10. Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy.
Lindauer A; Laveille C; Stockis A
Clin Pharmacokinet; 2017 Nov; 56(11):1403-1413. PubMed ID: 28290119
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double-blind study.
Baulac M; Patten A; Giorgi L
Epilepsia; 2014 Oct; 55(10):1534-43. PubMed ID: 25109239
[TBL] [Abstract][Full Text] [Related]
13. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.
Powell G; Saunders M; Marson AG
Cochrane Database Syst Rev; 2010 Jan; (1):CD007124. PubMed ID: 20091617
[TBL] [Abstract][Full Text] [Related]
14. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.
Powell G; Saunders M; Rigby A; Marson AG
Cochrane Database Syst Rev; 2014 Dec; (12):CD007124. PubMed ID: 25470302
[TBL] [Abstract][Full Text] [Related]
15. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.
Powell G; Saunders M; Marson AG
Cochrane Database Syst Rev; 2014 Feb; (2):CD007124. PubMed ID: 24488654
[TBL] [Abstract][Full Text] [Related]
16. Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results from a multicenter, open-label trial.
Vossler DG; Wechsler RT; Williams P; Byrnes W; Therriault S;
Epilepsia; 2016 Oct; 57(10):1625-1633. PubMed ID: 27528101
[TBL] [Abstract][Full Text] [Related]
17. A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study.
Runge U; Arnold S; Brandt C; Reinhardt F; Kühn F; Isensee K; Ramirez F; Dedeken P; Lauterbach T; Noack-Rink M; Mayer T
Epilepsia; 2015 Dec; 56(12):1921-30. PubMed ID: 26526971
[TBL] [Abstract][Full Text] [Related]
18. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.
Powell G; Saunders M; Rigby A; Marson AG
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD007124. PubMed ID: 27933615
[TBL] [Abstract][Full Text] [Related]
19. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials.
Chung S; Ben-Menachem E; Sperling MR; Rosenfeld W; Fountain NB; Benbadis S; Hebert D; Isojärvi J; Doty P
CNS Drugs; 2010 Dec; 24(12):1041-54. PubMed ID: 21090838
[TBL] [Abstract][Full Text] [Related]
20. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton C; Hughes DA; Williamson P; Baker GA; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE;
Lancet; 2021 Apr; 397(10282):1363-1374. PubMed ID: 33838757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
